Related Experiment Video
Updated: Jan 12, 2026
Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
Published on: March 29, 2019
Nectin-4 in bladder cancer: biology and predictive biomarker potential
Navid Roessler1,2, Marcin Miszczyk1,3, Walter Berger4
1Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Purpose Of Review:
This review aims to summarize the biology and clinical relevance of Nectin-4 in patients with advanced bladder cancer, with a focus on its role as a therapeutic target and predictive biomarker.
Recent Findings:
Nectin-4 is consistently overexpressed in advanced bladder cancer, facilitating tumor progression and survival signaling. Its cell surface localization makes it an ideal target for antibody-drug conjugates (ADCs), such as enfortumab vedotin, which has shown excellent efficacy in both first-line treatment, post platinum-based chemotherapy, and following immune checkpoint inhibitors. Recent insights highlight Nectin-4 as potential predictive biomarker and a target for advanced medical imaging strategies. Resistance mechanisms and new combination approaches are currently being investigated.
Summary:
Nectin-4 is a key therapy target in patients with advanced bladder cancer, as demonstrated by the success of enfortumab vedotin. Emerging ADC technologies and Nectin-4-targeted imaging tools could improve efficacy and patient selection, redefining both diagnostic and therapeutic approaches.
